Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Capricor Therapeutics (CAPR) Equity Ratio (2016 - 2025)

Capricor Therapeutics (CAPR) has 15 years of Equity Ratio data on record, last reported at 0.66 in Q3 2025.

  • For Q3 2025, Equity Ratio fell 9.68% year-over-year to 0.66; the TTM value through Sep 2025 reached 0.66, down 9.68%, while the annual FY2024 figure was 0.85, 121.73% up from the prior year.
  • Equity Ratio reached 0.66 in Q3 2025 per CAPR's latest filing, down from 0.79 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.85 in Q4 2024 and bottomed at 0.05 in Q3 2023.
  • Average Equity Ratio over 5 years is 0.5, with a median of 0.38 recorded in 2023.
  • Peak YoY movement for Equity Ratio: tumbled 116.82% in 2023, then soared 1626.31% in 2024.
  • A 5-year view of Equity Ratio shows it stood at 0.76 in 2021, then crashed by 69.0% to 0.24 in 2022, then surged by 63.56% to 0.38 in 2023, then surged by 121.73% to 0.85 in 2024, then dropped by 22.26% to 0.66 in 2025.
  • Per Business Quant database, its latest 3 readings for Equity Ratio were 0.66 in Q3 2025, 0.79 in Q2 2025, and 0.83 in Q1 2025.